心血管

Driving success in cardiology trials from early phase to post-approval

Advance your cardiology drug or device development with a team focused on the right sites and the best outcomes for patients.

Partner with cardiologists, project managers and strategists with deep drug discovery and clinical development experience.

Incorporate a rigorous approach to study design development and endpoint selection with significant expertise in the use of imaging, in vitro and digital endpoints.

Serving as your partner for comprehensive cardiology clinical trials.

Whether you need support with early phase adaptive trial design, site selection, patient identification or targeted services for late-phase outcomes trials, you can trust the expertise of an agile and experienced partner.

Fortrea's dedicated, global cardiovascular team-backed by industry leaders in medical, operational, and strategy-serves as a committed partner with the expertise and experience to deliver a comprehensive trial solution that fits your organization's business and strategy. Together, let's bring novel cardiovascular therapies to market and help deliver breakthroughs that change lives.

Experience matters when choosing a partner

让我们共同探讨

We've been honored to serve as a CRO partner of choice for our biotech and pharmaceutical customers as we've advanced their cardiovascular programs. In the last 5 years, we have supported:

375+

Cardiology Studies

9,720+

研究中心

146,500+

患者

主要适应症

Atherosclerotic cardiovascular disease (ASCVD)
Heart failure and cardiomyopathies
Hyperlipidemia
Acute coronary syndromes
Cardiovascular devices

Get the latest updates from our cardiovascular team

我们分享我们的最新动态、活动和出版物。

白皮书

Cardiovascular outcome trials: strategic insights for country and site distribution

Read the white paper

白皮书

Cardio-metabolic rare diseases: strategic insights for country and site distibution

Read the white paper

文章

通过多元化和包容性促进患者获得创新性心脏医疗器械治疗的机会

Read the article

Expect full support for your cardiology trial

Beyond our novel solutions, industry-leading processes, and subject matter expertise for your cardiovascular trial, we can offer our:

Recent and relevant experience in a large portfolio of CV trials from
early phase to registrational and post-approval.
Extensive ongoing site relationships along with our Xcellerate® trial data with extensive central laboratory data* and other data sources to enhance site selection and maximize patient recruitment. (*Fortrea will maintain exclusive CRO access to the Labcorp data that supports its clinical-enabling solutions for a fixed period of time)
Close collaboration with core labs to train and qualify sites in your necessary imaging and protocol procedures.
Endpoint “fast track strategies” and adjudication that result in more robust data for DMC/DSMB safety reviews—and no delays to database lock.